TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
- Conditions
- HIV InfectionsTuberculosis
- Registration Number
- NCT00023361
- Lead Sponsor
- Centers for Disease Control and Prevention
- Brief Summary
Primary objective:
To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 215
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Rate of confirmed treatment failure and relapse
- Secondary Outcome Measures
Name Time Method Safety and tolerability Response of HIV RNA to TB treatment Paradoxical reactions
Trial Locations
- Locations (23)
Central Arkansas Veterans Health System
🇺🇸Little Rock, Arkansas, United States
LA County/USC Medical Center
🇺🇸Los Angeles, California, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
Denver Department of Public Health and Hospitals
🇺🇸Denver, Colorado, United States
Washington, D.C. VAMC
🇺🇸Washington, District of Columbia, United States
Chicago VA Medical Center (Lakeside)
🇺🇸Chicago, Illinois, United States
Hines VA Medical Center
🇺🇸Hines, Illinois, United States
Johns Hopkins University School of Medicine
🇺🇸Baltimore, Maryland, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
New Jersey Medical School
🇺🇸Newark, New Jersey, United States
Scroll for more (13 remaining)Central Arkansas Veterans Health System🇺🇸Little Rock, Arkansas, United States